Brainstorm Cell Therapeutics
BCLI

$0.35

3.01%

Market Cap: 28M

About: Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

Employees: 29

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

0

News positive %

of 4 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

6,500% more call options, than puts

Call options by funds: $66K | Put options by funds: $1K

111% more capital invested

Capital invested by funds: $1.04M [Q4 2023] → $2.19M (+$1.15M) [Q1 2024]

0.17% more ownership

Funds ownership: 8.08% [Q4 2023] → 8.25% (+0.17%) [Q1 2024]

0% more funds holding

Funds holding: 46 [Q4 2023] → 46 (+0) [Q1 2024]

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

50% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 10

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target

$2

469%

upside

Avg. target

$2

469%

upside

High target

$2

469%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Maxim Group

Jason McCarthy

469%upside

$2

Buy

Upgraded

11 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about BCLI published over the past 30 days

BCLI Update - Progress Supports Our 10x Plus Value Range Potential

ACF Equity Research FROM ACF EQUITY RESEARCH HEALTHCARE TEAM LONDON , July 24, 2024 /PRNewswire/ -- NASDAQ: BCLI READ ACF EQUITY RESEARCH'S UPDATE NOTE HERE READ ACF EQUITY RESEARCH'S RELATED THEMATIC RESEARCH NOTE ON REGENERATIVE MEDICINE – NEURODEGENERATIVE DISEASE STEM CELLS & ALS/MND/LOU GEHRIG'S HERE UPDATE NOTE: BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) develops NurOwn® stem cell therapy for Neurodegenerative diseases (NDDs) – BCLI's first target is ALS (MND/Lou Gehrig's). Since initiation – PIIIb rollout begins.

BCLI Update - Progress Supports Our 10x Plus Value Range Potential

Brainstorm Cell Therapeutics Inc. (BCLI) Corporate Mid-Year Update on NurOwn Program (Transcript)

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI ) Corporate Mid-Year Update on NurOwn Program July 8, 2024 8:00 AM ET Company Participants Joyce Lonergan - LifeSci Advisors Chaim Lebovits - President and Chief Executive Officer Haro Hartounian - Executive Vice President, Chief Operating Officer Bob Dagher - Executive Vice President, Chief Medical Officer Conference Call Participants Jason McCarthy - Maxim Group David Bautz - Zachs Small Cap Research Operator Greetings and welcome to the Brainstorm Cell Therapeutics Mid-Year 2024 Conference Call. At this time, all participants are in a listen-only mode.

Brainstorm Cell Therapeutics Inc. (BCLI) Corporate Mid-Year Update on NurOwn Program (Transcript)

BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program

A conference call and webcast will be held Monday, July 8, at 8:00 a.m. Eastern Time NEW YORK , July 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a mid-year corporate update to discuss recent positive developments in the NurOwn® program on Monday, July 8, at 8:00 a.m.

BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program

BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering

NEW YORK , June 27, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) (the "Company"), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has entered into a securities purchase agreement with a single institutional investor (the "Holder") for the purchase and sale of 11,111,111 shares of the Company's common stock (or prefunded warrants in lieu thereof) at a purchase price of $0.36 per share in a registered direct offering. In a concurrent private placement, the Company has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 16,666,667 shares of its common stock.

BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering

BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial

NEW YORK , June 26, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced it has reached alignment with the U.S. Food and Drug Administration (FDA) on the Chemistry, Manufacturing, and Controls (CMC) aspects of Brainstorm's Phase 3b clinical trial for NurOwn®, its investigational therapy for amyotrophic lateral sclerosis (ALS). This Type C meeting builds upon the positive momentum established in April 2024, when the FDA granted BrainStorm a Special Protocol Assessment (SPA) agreement for its NurOwn Phase 3b trial.

BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial

BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer

Appointment Completes Executive Readiness for Registrational Phase 3b ALS Study Launch NEW YORK , June 20, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Hartoun Hartounian Ph.D. as its new EVP and COO, effective as of June 18, 2024.

BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer

BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation

FROM ACF EQUITY RESEARCH HEALTHCARE TEAM NASDAQ: BCLI READ ACF EQUITY RESEARCH'S INITIATION NOTE HERE READ ACF EQUITY RESEARCH'S RELATED THEMATIC RESEARCH NOTE ON REGENERATIVE MEDICINE – NEURODEGENERATIVE DISEASE STEM CELLS & ALS/MND/LOU GEHRIG'S HERE LONDON , June 14, 2024 /PRNewswire/ -- INITIATION NOTE: BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) is focused on developing autologous mesenchymal stem cell (MSC) therapies for the treatment of neurodegenerative diseases (NDDs) – BCLI's primary target is the fatal amyotrophic lateral sclerosis (ALS/MND/Lou Gehrig's). Post hoc analysis of BCLI's PIII trial data shows BCLI's NurOwn® (debamestrocel, MSC-NTF), has statistically significant clinical effects on early-stage ALS sufferers and that placebo trialists deteriorate faster.

BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation

BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn

The data will be presented at the Annual ALS Drug Development Summit, which is focused on identifying transformative ALS targets, seeking translational biomarkers and propelling more clinical approvals NEW YORK , May 20, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, will present new biomarker data suggesting that ALS patients may benefit from longer-term treatment with debamestrocel (NurOwn®). The Company will share the data with an international audience of patient advocacy groups, physicians, research organizations, industry representatives, key thought leaders and decision makers dedicated to ALS research at The 3rd Annual ALS Drug Development Summit, to take place May 21 to 23, 2024 in Boston MA.

BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn

BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Company received written agreement from the U.S. FDA under a Special Protocol Assessment (SPA) on the design for a Phase 3b trial of NurOwn® Conference call planned for later this quarter to provide update on NurOwn program NEW YORK , May 14, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the First Quarter ended March 31, 2024 and provided a corporate update. "We recently achieved an important milestone on our Debamestrocel (NurOwn®) development program, reaching agreement with the US FDA on a Special Protocol Assessment for our planned Phase 3b trial of NurOwn.

BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn

Bob Dagher, MD, Promoted to Chief Medical Officer Dr. Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of Directors NEW YORK , April 16, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the promotion of Dr. Bob Dagher to Executive Vice President and Chief Medical Officer. In addition, after four years of maintaining top executive roles, Dr. Stacy Lindborg stepping down from the role of Co-CEO and will remain with BrainStorm as a member of its Board of Directors.

BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn

See News Rankings